Cargando…
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case
BACKGROUND: Intranasal delivery of NEO100, a pharmaceutical-grade version of the natural monoterpene perillyl alcohol (POH), is undergoing clinical phase IIa testing as a treatment for glioblastoma (GBM). However, so far there is no evidence that intranasal delivery of NEO100 indeed results in POH r...
Autores principales: | Schönthal, Axel H., Swenson, Steve, Bonney, Phillip A., Wagle, Naveed, Simmon, Vincent F., Mathew, Anna J., Hurth, Kyle M., Chen, Thomas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Neurological Surgeons
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706323/ https://www.ncbi.nlm.nih.gov/pubmed/36088606 http://dx.doi.org/10.3171/CASE22215 |
Ejemplares similares
-
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma
por: Schönthal, Axel H, et al.
Publicado: (2021) -
Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice
por: Cho, Hee-Yeon, et al.
Publicado: (2020) -
Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development
por: Chen, Thomas C., et al.
Publicado: (2018) -
Cytotoxic impact of a perillyl alcohol–temozolomide conjugate,
NEO212, on cutaneous T-cell lymphoma in vitro
por: Silva-Hirschberg, Catalina, et al.
Publicado: (2019) -
NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity
por: Chen, Thomas C., et al.
Publicado: (2022)